Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in Acute-on-Chronic Liver Failure
NCT03737448Phase 1Suspended
- Sponsor
- Martin Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of trimetazidine in liver failure (2 arms), sponsored by Martin Pharmaceuticals. Primary endpoint: Plasma Pharmacokinetics at 28 days. Started Nov 2018; status: suspended.
02
Drugs
trimetazidine
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT03737448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737448.